Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Kaniz Afroz TanniCong Bang TruongSura AlmahasisJingjing QianPublished in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2021)
Our findings support the similarity in the signals of disproportionate reporting between cancer supportive care originator biologics and biosimilars, except for Fulphila®.